Literature DB >> 34821967

Image quality in liver CT: low-dose deep learning vs standard-dose model-based iterative reconstructions.

Sungeun Park1,2, Jeong Hee Yoon1,3,4, Ijin Joo1,3, Mi Hye Yu5, Jae Hyun Kim1,3, Junghoan Park1, Se Woo Kim1, Seungchul Han1,3, Chulkyun Ahn6,7, Jong Hyo Kim3,6,7,8, Jeong Min Lee9,10,11.   

Abstract

OBJECTIVES: To compare the overall image quality and detectability of significant (malignant and pre-malignant) liver lesions of low-dose liver CT (LDCT, 33.3% dose) using deep learning denoising (DLD) to standard-dose CT (SDCT, 100% dose) using model-based iterative reconstruction (MBIR).
METHODS: In this retrospective study, CT images of 80 patients with hepatic focal lesions were included. For noninferiority analysis of overall image quality, a margin of - 0.5 points (scored in a 5-point scale) for the difference between scan protocols was pre-defined. Other quantitative or qualitative image quality assessments were performed. Additionally, detectability of significant liver lesions was compared, with 64 pairs of CT, using the jackknife alternative free-response ROC analysis, with noninferior margin defined by the lower limit of 95% confidence interval (CI) of the difference of figure-of-merit less than - 0.1.
RESULTS: The mean overall image quality scores with LDCT and SDCT were 3.77 ± 0.38 and 3.94 ± 0.34, respectively, demonstrating a difference of - 0.17 (95% CI: - 0.21 to - 0.12), which did not cross the predefined noninferiority margin of - 0.5. Furthermore, LDCT showed significantly superior quantitative results of liver lesion contrast to noise ratio (p < 0.05). However, although LDCT scored higher than the average score in qualitative image quality assessments, they were significantly lower than those of SDCT (p < 0.05). Figure-of-merit for lesion detection was 0.859 for LDCT and 0.878 for SDCT, showing noninferiority (difference: - 0.019, 95% CI: - 0.058 to 0.021).
CONCLUSION: LDCT using DLD with 67% radiation dose reduction showed non-inferior overall image quality and lesion detectability, compared to SDCT. KEY POINTS: • Low-dose liver CT using deep learning denoising (DLD), at 67% dose reduction, provided non-inferior overall image quality compared to standard-dose CT using model-based iterative reconstruction (MBIR). • Low-dose CT using DLD showed significantly less noise and higher CNR lesion to liver than standard-dose CT using MBIR and demonstrated at least average image quality score among all readers, albeit with lower scores than standard-dose CT using MBIR. • Low-dose liver CT showed noninferior detectability for malignant and pre-malignant liver lesions, compared to standard-dose CT.
© 2021. The Author(s), under exclusive licence to European Society of Radiology.

Entities:  

Keywords:  Deep learning; Multidetector computed tomography; Radiation dosage

Mesh:

Year:  2021        PMID: 34821967     DOI: 10.1007/s00330-021-08380-0

Source DB:  PubMed          Journal:  Eur Radiol        ISSN: 0938-7994            Impact factor:   5.315


  3 in total

1.  Region of Interest (ROI) Computed Tomography.

Authors:  R Chityala; K R Hoffmann; D R Bednarek; S Rudin
Journal:  Proc SPIE Int Soc Opt Eng       Date:  2004

2.  Noise and spatial resolution properties of a commercially available deep learning-based CT reconstruction algorithm.

Authors:  Justin Solomon; Peijei Lyu; Daniele Marin; Ehsan Samei
Journal:  Med Phys       Date:  2020-07-06       Impact factor: 4.071

3.  Automatic Detection of Inadequate Pediatric Lateral Neck Radiographs of the Airway and Soft Tissues using Deep Learning.

Authors:  Elanchezhian Somasundaram; Jonathan R Dillman; Eric J Crotty; Andrew T Trout; Alexander J Towbin; Christopher G Anton; Angeline Logan; Catherine A Wieland; Samantha Felekey; Brian D Coley; Samuel L Brady
Journal:  Radiol Artif Intell       Date:  2020-09-30
  3 in total
  1 in total

1.  Fully automated image quality evaluation on patient CT: Multi-vendor and multi-reconstruction study.

Authors:  Minsoo Chun; Jin Hwa Choi; Sihwan Kim; Chulkyun Ahn; Jong Hyo Kim
Journal:  PLoS One       Date:  2022-07-20       Impact factor: 3.752

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.